Ensysce Biosciences Reports Q3 2026 Results, $29.7 Million Cash Balance

Ensysce Biosciences reported a third-quarter 2026 net loss attributable to common stockholders of $82.3 million, including a one-time, non-cash acquired research and development charge of about $79.9 million. Cash and cash equivalents totaled $29.7 million at September 30, 2026. During the quarter…